A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
← catalyst calendarNCT07287098 · readout ≤ 896 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
600estimated
Sites
86
Countries
Belgium, France, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-13 | actual | When the study began enrolling |
| Primary completion | Jan 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Neoplasms
Interventions
- Drug: Imlunestrant — also filed as LY3484356
- Drug: Goserelin
- Drug: Tamoxifen 20 mg
Primary outcomes
what the primary-completion date above is the date OFChange from Baseline in Antigen Kiel (Ki-67) Expression
measured Baseline, Day 29
Rate of Symptomatic Ovarian Cysts
measured Up to Day 180
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed